The large armamentarium of therapies available today for metastatic clear cell renal cell carcinoma (mCCRCC) has prolonged the survival of these patients in real-life as many of them are treated outside clinical trials with a sequential treatment strategy.
No takes yet. Share an insight, caveat, or question.
Angulo et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: